Yeti downgraded, Humana upgraded: Wall Street's top analyst calls

RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.

Original reporting
Published Nov 16, 2026, 2:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Yeti downgraded, Humana upgraded: Wall Street's top analyst calls — source image
Decision brief

The 30-second read

$HUMBullishMed
01

Why it matters

For traders, the actionable element is the direction and magnitude of rating/PT changes, especially where the article cites concrete negatives (Cogent going-concern warning, Yeti demand softness) or pre-earnings positioning (Viking ahead of Q3).

02

Market read

This is a sentiment and positioning update across multiple U.S.-listed stocks, with the highest trader focus on downgrades tied to explicit risk signals and large PT cuts.

03

What to watch

Several theses hinge on assumptions (transitory river levels, domestic demand softness, cost pressure build) that could reverse quickly with new data, making the near-term reaction potentially noisy.

Relevance 5/10Novelty 5/10Timing: today’s analyst rating and price-target changes

Background

The article is a multi-name analyst note roundup featuring upgrades, downgrades, and coverage initiations with updated price targets and stated theses.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

RBC upgraded Humana to Outperform and raised its price target to $563, citing a Stars turnaround and disciplined medical cost management.

Expected impact

Likely upward pressure as traders price in improved earnings trajectory and higher-conviction analyst expectations.

Evidence & confidence

The article contains a clear rating change plus a materially higher price target tied to specific operational drivers.

$SPXCNeutralMedium confidence
Context

TD Cowen upgraded SPX Technologies to Buy and cut its price target to $200, calling current levels a more palatable entry for the same growth profile.

Expected impact

Mixed reaction likely, with upside bias from the upgrade offset by skepticism implied by the PT cut.

Evidence & confidence

The direction is ambiguous because the article pairs an upgrade with a reduced price target.

$ABNBBullishMedium confidence
Context

Phillip Securities upgraded Airbnb to Neutral from Reduce and raised its price target to $184 after the Q3 report, citing higher revenue growth and margins.

Expected impact

Likely modest upward bias as the market digests improved fundamentals assumptions versus the prior downgrade stance.

Evidence & confidence

The article provides a PT increase and specific operating drivers, but the rating is only Neutral.

$TXRHBullishHigh confidence
Context

Gordon Haskett upgraded Texas Roadhouse to Buy and raised its price target to $220, citing accelerating traffic recovery across U.S. regions.

Expected impact

Likely upward pressure as traders align with the view of accelerating traffic recovery.

Evidence & confidence

Clear upgrade plus higher PT anchored to a concrete demand trend.

$VIKBullishMedium confidence
Context

Mizuho double upgraded Viking Holdings to Outperform and lifted its price target to $120 ahead of the Q3 report, arguing river-level weakness is transitory.

Expected impact

Likely upward pressure as the market anticipates normalization of river levels and improved earnings power.

Evidence & confidence

The thesis is specific, but it is still pre-Q3 and depends on the transitory assumption.

$YETIBearishHigh confidence
Context

Goldman Sachs downgraded Yeti to Neutral from Buy and cut its price target to $41 after the Q3 report, citing softer domestic demand and rising cost pressures into 2027.

Expected impact

Likely downward pressure as traders reprice risk from weaker domestic demand and cost build.

Evidence & confidence

The article provides a direct downgrade and PT cut with explicit forward-looking drivers.

$FMCBearishMedium confidence
Context

KeyBanc downgraded FMC to Sector Weight from Overweight, saying crop-chemical demand and pricing look weaker than expected, especially in South America.

Expected impact

Likely downside or underperformance pressure as the market adjusts to weaker demand/pricing assumptions.

Evidence & confidence

No PT is provided, but the downgrade is supported by a specific regional demand/pricing critique.

$USARNeutralMedium confidence
Context

William Blair downgraded USA Rare Earth to Market Perform from Outperform, noting feedstock shortages as near-term challenges despite potential upside.

Expected impact

Likely limited upside or mild downside as investors focus on feedstock-driven delays.

Evidence & confidence

The article includes a downgrade and a challenge, but lacks a PT and quantification.

Market effects

Broad read-through across managed care, travel/leisure, industrials, and consumer discretionary, but the piece is primarily single-name analyst positioning.

No direct regional macro catalyst; impacts are stock-specific in U.S. trading.

Includes a foreign-listed name (Bilibili) but the drivers cited are company-specific monetization risk rather than global macro.

Counterpoint

Analyst PT changes may be less predictive than upcoming company-specific catalysts (e.g., Viking’s Q3) and near-term earnings revisions, so price may not follow immediately.

Key entities

  • Humana

    Upgraded to Outperform with a raised $563 price target, citing Stars turnaround and medical cost discipline.

  • Yeti

    Downgraded to Neutral with a cut $41 price target after Q3, citing softer domestic demand and rising cost pressures.

  • Cogent

    Downgraded to Underweight with a cut $4 price target, citing missed Q3 estimates, going-concern warning, and suspended dividend.

Related articles

$VIKMedAI 8/10

Viking Q3 2026 slides: water woes dent margins, bookings stay strong

Viking Holdings (VIK) reported Q3 2026 revenue growth of 9.2% to $2.18B, but net income fell due to low European water levels affecting river cruises. Adjusted EPS missed estimates at $1.11. The stock dropped 4.3% premarket. Despite disruptions, bookings for 2027 are strong at $5.8B, and the company has $4.1B in cash. Ocean cruises are a growth focus, with capacity expanding through 2036.

$HUMMed

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

HUMANA INC (HUM) filed an SEC Form 8-K — Other Events. news release Humana Inc. 101 East Main Street Louisville, KY 40202 Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“ Humana ”, “ we ”, or “ our ”) today announce

$VIKMedAI 8/10

Why is Viking stock falling today?

Viking Holdings Ltd (VIK) stock fell 3.5% in pre-market trading after reporting Q3 2026 earnings of $1.11 per share, missing estimates and prior results. Revenue grew 9.2% YoY to $2.18B but missed forecasts. Europe's 2026 drought disrupted river cruises, reducing occupancy and yield. Insider selling added pressure, while Mizuho upgraded the stock to Outperform with a $120 target. 2027 bookings are up 17% YoY.